Updates are available Correction dated 2026-03-18
Click to view Correction: https://doi.org/10.1007/s13555-026-01671-8
-
Authors
Yosipovitch, Gil
Kim, Brian S.
Koo, John Y.
Chen, Zhen
Wiggins, Simmi
Zahn, Joseph
Sugerman, Philip
Haddad, El-Bdaoui
Cyr, Sonya L. https://orcid.org/0000-0002-7231-0054
-
Funding
Funding for this research was provided by:
Sanofi
Regeneron Pharmaceuticals
- License Information
-
More Information
Article History
Received: 26 August 2025
Accepted: 4 November 2025
First Online: 22 November 2025
Change Date: 18 March 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s13555-026-01671-8
Declarations
:
: Gil Yosipovitch is an advisory board member for AbbVie, Amgen, Arcutis Biotherapeutics, Attovia, Eli Lilly, Escient Pharmaceuticals, Galderma, GSK, Incyte, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals Inc., Sanofi, and Vifor; has received grants/research funding from Amgen, Celldex, Eli Lilly, Escient Pharmaceuticals, Galderma, Kiniksa, LEO Pharma, Novartis, Pfizer, Sanofi-Regeneron Pharmaceuticals Inc.; is an investigator for Regeneron Pharmaceuticals Inc. and Sanofi; and provides research support and is a consultant for Regeneron Pharmaceuticals Inc. Brian S. Kim is a consultant for AbbVie, Abrax Japan, Almirall, Alys Pharmaceuticals, Cara Therapeutics, Clexio Biosciences, Eli Lilly, Escient Pharmaceuticals, Evommune, Galderma, Neurommune Therapeutics, Novartis, Pfizer, RecensMedical, Regeneron Pharmaceuticals Inc., Sanofi, and Septerna; and he is also co-founder of Alys Pharmaceuticals and Neurommune Therapeutics. John Y. Koo has been a speaker and/or consultant for AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Castle, Dermavant, Eli Lilly, EPI, Incyte, Janssen, LEOÂ Pharma, Novartis, Ortho Dermatologics/Valeant, Pfizer, Regeneron Pharmaceuticals Inc./Sanofi, Sun, and UCB. Zhen Chen, Joseph Zahn, and Sonya L. Cyr are employees and shareholders of Regeneron Pharmaceuticals Inc. Simmi Wiggins, Philip Sugerman, and El-Bdaoui Haddad are Sanofi employees and may hold stock and/or stock options in the company.
: The studies included in this analysis were conducted in accordance with the protocol and consensus ethical principles derived from international guidelines, including the Declaration of Helsinki (1964) and other applicable laws and regulations. Authors received participants’ consent to participate. Each participant provided written informed consent to participate and publish prior to their participation in the study.
